Novo Nordisk A/S (NYSE:NVO) Rating Lowered to Accumulate at Handelsbanken

Novo Nordisk A/S (NYSE:NVO) was downgraded by equities researchers at Handelsbanken from a “buy” rating to an “accumulate” rating in a note issued to investors on Monday, February 4th. They currently have a $48.61 price objective on the stock. Handelsbanken’s target price would suggest a potential downside of 2.00% from the company’s current price.

Several other analysts also recently weighed in on NVO. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. UBS Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, November 26th. ValuEngine raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, October 27th. Kepler Capital Markets reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, November 29th. Finally, Cfra reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $52.31.

NYSE NVO traded up $0.65 during trading on Monday, hitting $49.60. The stock had a trading volume of 1,482,986 shares, compared to its average volume of 1,353,264. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $51.64. The company has a market cap of $121.64 billion, a P/E ratio of 19.68, a PEG ratio of 2.34 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Friday, February 1st. The company reported $0.54 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.03). Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. The company had revenue of $4.55 billion for the quarter, compared to the consensus estimate of $4.36 billion. As a group, research analysts predict that Novo Nordisk A/S will post 2.58 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Roundview Capital LLC grew its holdings in Novo Nordisk A/S by 1.3% in the fourth quarter. Roundview Capital LLC now owns 16,870 shares of the company’s stock worth $777,000 after purchasing an additional 210 shares during the last quarter. Garrison Financial Corp grew its holdings in Novo Nordisk A/S by 2.5% in the fourth quarter. Garrison Financial Corp now owns 12,510 shares of the company’s stock worth $576,000 after purchasing an additional 300 shares during the last quarter. Edmond DE Rothschild Holding S.A. grew its holdings in Novo Nordisk A/S by 2.4% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 13,702 shares of the company’s stock worth $632,000 after purchasing an additional 324 shares during the last quarter. Advisor Partners LLC lifted its stake in shares of Novo Nordisk A/S by 2.7% during the fourth quarter. Advisor Partners LLC now owns 12,634 shares of the company’s stock worth $582,000 after buying an additional 338 shares during the period. Finally, Dorsey & Whitney Trust CO LLC lifted its stake in shares of Novo Nordisk A/S by 6.7% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 6,727 shares of the company’s stock worth $310,000 after buying an additional 420 shares during the period. 6.88% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: What is Cost of Debt?

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.